Navigation Links
McMaster scientists find protein’s bad guy role in prostate cancer
Date:5/10/2011

Hamilton, ON (May 10, 2011) It's a disease affecting those closest to us our fathers, brothers and sons.

Prostate cancer impacts one in six men in Canada. Last year, roughly 24,600 men were diagnosed with the disease.

Most types of prostate cancer are curable if caught and treated early. But little is understood about the mechanisms that cause a tumour to metastasize and spread to other parts of the body.

Damu Tang, an associate professor of medicine in the Division of Nephrology of the McMaster University's Michael G. DeGroote School of Medicine and St. Joseph's Healthcare Hamilton, has spent nearly a decade and searched more than a million genes to better understand the molecular underpinnings of prostate cancer progression.

His research, published today in Nature Communications, shows for the first time the role of a specific protein MAN2C1 in prostate cancer development. The finding is significant because prostate cancer patients with increased levels of MAN2C1 appear to face more aggressive forms of the disease.

"This research could serve a diagnostic purpose in terms of likelihood of whether prostate cancers at early stages will progress into metastatic tumours," said Tang, who has a joint appointment in the Division of Urology, Department of Surgery at McMaster. "Patients with high levels of MAN2C1 may need more aggressive therapies when their cancers are still at early stages in order to prevent the development of metastatic cancer."

It's been known for some time that another protein, PTEN, is a powerful tumour suppressor. Clinical observations have shown that half of advanced prostate cancers either have no PTEN or reduced PTEN function.

Tang and his research team set out to understand how PTEN function becomes impaired in advanced prostate cancers. In the process, they discovered MAN2C1 and the role it plays in reducing PTEN function.

The research group found increases in the MAN2C1 protein in PTEN-positive prostate cancer cells dramatically increased the likelihood of cancers forming in mice. Additional research showed that in 659 prostate cancer patients, approximately 60 per cent of their prostate tumors had normal PTEN. Among these tumors, 80 per cent had increased MAN2C1.

The researchers concluded that increases in MAN2C1 in PTEN-positive prostate cancers enhance prostate cancer recurrence, meaning that patients with high levels of MAN2C1 have an increased risk of their tumors developing into metastatic cancer.

The next step for the researchers will be to look for ways to block the ability of MAN2C1 to impair PTEN function, Tang said. That could lead to the development of new therapies for patients with prostate cancer.


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
905-525-9140 x22169
McMaster University
Source:Eurekalert

Related medicine news :

1. McMaster researcher leads development of promising drug for inflammation
2. McMaster study contradicts reports of problems with blood-thinner
3. Youth with IBD are less fit than their peers: McMaster study
4. McMaster vaccine has pet owners feline groovy
5. Scientists Pinpoint Area of Brain That Fears Losing Money
6. Scientists Discover How HIV Is Transmitted Between Men
7. Prevention Is Key Research Goal for Premature Babies, Scientists Say
8. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
9. Scientists find donut-shaped structure of enzyme involved in energy metabolism
10. Neuroscientists reveal new links that regulate brain electrical activity
11. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/19/2017)... (PRWEB) , ... January 20, 2017 , ... Today, the ... to participate in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who ... patients. APMs are an important part of the Administration’s effort to build a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... This month, the ... that the name of their drug rehab center in Delray Beach, Florida has been ... that not only stars such as Philip Seymour Hoffman and Chris Farley are dying ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology: